论文部分内容阅读
目的观察丁苯酞治疗急性脑梗死的临床疗效及安全性。方法选择发病48h以内入院的脑梗死患者68例,随机分为丁苯酞奉组(36例)及常规治疗组(32例)。常规治疗组给予血塞通、阿司匹林,丁苯酞组在常规治疗基础上给予丁苯酞0.2g tid,4次/d,共14d。两组在治疗前后进行美国国立卫生研究院卒中量表评分(NIHSS)、日常生活能力(ADL)评分判断其疗效并观察其不良反应。结果治疗后丁苯酞组NIHSS、ADL评分明显优于常规治疗组(P<0.05),丁苯酞组临床有效率及显效率均显著高于常规治疗组(P<0.05)。丁苯酞组无明显不良反应。结论丁苯酞治疗急性脑梗死安全有效。
Objective To observe the clinical efficacy and safety of butylphthalide in the treatment of acute cerebral infarction. Methods Sixty-eight patients with cerebral infarction admitted within 48 hours after onset were randomly divided into 3 groups: butylphthalide (36 cases) and conventional treatment group (32 cases). Conventional treatment group given Xuesaitong, aspirin, butylphthalide group on the basis of conventional treatment given butylphthalide 0.2g tid, 4 times / d, a total of 14d. Before and after treatment, the two groups were rated NIHSS and ADL score to determine the efficacy and observe the adverse reactions. Results The NIHSS and ADL scores of the butylphthalide group were significantly better than those of the conventional treatment group (P <0.05). The clinical effective rate and the markedly effective rate of the butylphthalide group were significantly higher than those of the conventional treatment group (P <0.05). Butylphthalide group no obvious adverse reactions. Conclusion Butylphthalide treatment of acute cerebral infarction safe and effective.